Sartorius Stedim Biotech acquires Cellca

The financial details of the transaction are not disclosed


The acquisition helps in further expanding the company's service offering for process development

Sartorius Stedim Biotech (SSB) has acquired Germany-based Cellca, a cell line and process development company.

Through this acquisition, SSB is further expanding its service offering for process development. The company has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.

Mr Reinhard Vogt, member of the SSB executive committee for marketing and sales, said, "Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics."

"Due to its global presence and high reputation, SSB is an ideal partner for Cellca. We now have a strong base to further expand and develop our business internationally," said Mr Hugo de Wit, managing director, Cellca.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email